CalciMedica, Inc. Common Stock (CALC)vsRevolution Medicines Inc (RVMD)
CALC
CalciMedica, Inc. Common Stock
$0.99
+24.62%
HEALTHCARE · Cap: $12.89M
RVMD
Revolution Medicines Inc
$192.62
+5.79%
HEALTHCARE · Cap: $36.09B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
CALC
Avoid19
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CALC
CALC has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
CALC is growing revenue faster at 0.0% — sustainability is the question.
CALC generates stronger free cash flow (-5M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 19/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies that modulate calcium-dependent pathways to address acute and chronic health issues. Its lead candidate, CM4620, targets severe muscle cramps in patients with sickle cell disease, highlighting the company's commitment to tackling critical unmet medical needs. With a proprietary technology platform and a well-defined pipeline of novel calcium modulators, CalciMedica is well-positioned for growth. The company is supported by a seasoned management team and strategic partnerships aimed at accelerating its clinical development, making it a noteworthy investment opportunity in the biopharmaceutical landscape.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?